Anti-TNF prescribing survey Question Title * 1. What is your current role? General gastroenterologist Gastroenterologist with a particular interest in IBD General Surgeon General Physician Gastroenterology Trainee Other Question Title * 2. With regard to infliximab prescribing for IBD. Do you escalate dosing beyond those approved by Special authority criteria (5mg/Kg 8 weekly with provision for high dose re-induction)? Yes, often (>25% of patients) at higher than approved doses Yes, occasionally (1-25% of patients) at higher than approved doses I only use approved re-induction regimes to dose escalate No, only prescribe at standard dosing schedule No, my pharmacy will not allow escalated dosing Question Title * 3. If you escalate dosing of infliximab, what guides this decision? (select as many as apply) Clinical symptoms alone Therapeutic drug monitoring (TDM) alone Biomarkers alone Question Title * 4. If you prescribe escalated doses of infliximab, beyond special authority criteria, how do you access this? Hospital pharmacy supply dosing as prescribed Janssen supply extra dosing via compassionate access Other (please specify) Question Title * 5. With regard to adalimumab dosing, do you ever prescribe >40mg sc weekly? Yes No Question Title * 6. If yes please comment on how you access this? Question Title * 7. Do you have any comments on access to anti-TNF dose escalation in New Zealand? Done